ASCO 2023 | The future of enfortumab vedotin in different stages bladder cancer

Shilpa Gupta, MD, Cleveland Clinic, Cleveland, OH, describes the rationale and trial design of the EV-103 trial (NCT03288545), providing an overview of current trials assessing enfortumab vedotin (EV), an antibody-drug conjugate (ACD), in various settings for bladder cancer. Cohort H of the EV-103 trial (NCT03288545), which assessed neoadjuvant EV, included patients with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible and an encouraging improvement in pathological complete response rate was observed. Dr Gupta additionally highlights the KEYNOTE-905 trial (NCT03924895) of pembrolizumab and EV with cystectomy in patients with MIBC, as well as another trial assessing intravenous EV in MIBC. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.